Eric Perouzel
Overview
Explore the profile of Eric Perouzel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
586
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Lee S, Choi Y, Kang S, Lee M, Debin A, Perouzel E, et al.
Cancers (Basel)
. 2023 Dec;
15(24).
PMID: 38136298
Nexavant was reported as an alternative to the TLR3 agonist of Poly(I:C) and its derivatives. The physicochemical properties, signaling pathways, anti-cancer effects, and mechanisms of Nexavant were investigated. The distinctive...
2.
Joseph J, Blaavand M, Cai H, Vernejoul F, Knopper R, Lindhardt T, et al.
Cancer Lett
. 2023 Nov;
579:216480.
PMID: 37931834
Glioblastoma (GBM) is an aggressive brain tumor with a median survival of 15 months and has limited treatment options. Immunotherapy with checkpoint inhibitors has shown minimal efficacy in combating GBM,...
3.
Planes R, Pinilla M, Santoni K, Hessel A, Passemar C, Lay K, et al.
Mol Cell
. 2022 May;
82(13):2385-2400.e9.
PMID: 35594856
Inflammation observed in SARS-CoV-2-infected patients suggests that inflammasomes, proinflammatory intracellular complexes, regulate various steps of infection. Lung epithelial cells express inflammasome-forming sensors and constitute the primary entry door of SARS-CoV-2....
4.
Gutjahr A, Papagno L, Vernejoul F, Lioux T, Jospin F, Chanut B, et al.
EBioMedicine
. 2020 Aug;
58:102922.
PMID: 32739871
Background: PRR (Pattern Recognition Receptor) agonists have been widely tested as potent vaccine adjuvants. TLR7 (Toll-Like Receptor 7) and NOD2 (nucleotide-binding oligomerization domain 2) are key innate receptors widely expressed...
5.
Thomsen M, Skouboe M, Boularan C, Vernejoul F, Lioux T, Leknes S, et al.
Oncogene
. 2019 Nov;
39(8):1652-1664.
PMID: 31740782
Hepatocellular carcinoma (HCC) is the most common primary liver cancer, and the incidence of HCC is increasing. Recently, cancer immunotherapy has emerged as an efficient treatment against some cancers. Here...
6.
Gutjahr A, Papagno L, Nicoli F, Kanuma T, Kuse N, Cabral-Piccin M, et al.
JCI Insight
. 2019 Apr;
4(7).
PMID: 30944257
Pathogen recognition receptor (PRR) agonists are currently being developed and tested as adjuvants in various formulations to optimize the immunogenicity and efficacy of vaccines. Using an original in vitro approach...
7.
Skouboe M, Knudsen A, Reinert L, Boularan C, Lioux T, Perouzel E, et al.
PLoS Pathog
. 2018 Apr;
14(4):e1006976.
PMID: 29608601
In recent years, there has been an increasing interest in immunomodulatory therapy as a means to treat various conditions, including infectious diseases. For instance, Toll-like receptor (TLR) agonists have been...
8.
Gutjahr A, Papagno L, Nicoli F, Lamoureux A, Vernejoul F, Lioux T, et al.
J Immunol
. 2017 Apr;
198(11):4205-4209.
PMID: 28432147
TLR agonists are currently being developed and tested as adjuvants in various formulations to optimize the immunogenicity and efficacy of vaccines. The aim of this study was to evaluate the...
9.
Decout A, Silva-Gomes S, Drocourt D, Barbe S, Andre I, Cueto F, et al.
Proc Natl Acad Sci U S A
. 2017 Feb;
114(10):2675-2680.
PMID: 28223515
The advances in subunit vaccines development have intensified the search for potent adjuvants, particularly adjuvants inducing cell-mediated immune responses. Identification of the C-type lectin Mincle as one of the receptors...
10.
Gutjahr A, Tiraby G, Perouzel E, Verrier B, Paul S
Trends Immunol
. 2016 Sep;
37(10):716.
PMID: 27595229
No abstract available.